Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Suita-shi
Clinical trial register · Japan

Clinical Trials in Suita-shi, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company10 AstraZeneca7 AbbVie6 Alexion Pharmaceuticals, Inc.4 Novo Nordisk A/S3
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Suita-shi

46 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Kurume-shi, Sapporo, Kumamoto, Kyoto, Matsumoto-shi, Suita-shi, Bunkyo-ku, Shinjuku-ku
2027-11-23
Not yet open
Novo Nordisk A/S
Phase 3
400
Suita-shi, Sakai-shi, Osaka, Shinjuku-ku, Tokyo, Tokyo
2027-01-07
Recruiting
Novo Nordisk A/S
Phase 3
400
Sapporo, Yamato-shi, Chigasaki-shi, Kawasaki-shi, Suita-shi, Aichi, Bunkyo-ku, Tokyo, Chiba
2026-09-07
Recruiting
Eli Lilly and Company
Phase 3
2,001
Chūōku, Suita-shi, Tsuchiura
2026-08-26
Recruiting
A Study of LY3971297 in Participants With Heart Failure
NCT07547540Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic
Eli Lilly and Company
Phase 1
90
Kobe, Kyoto, Suita-shi, Tsuchiura-shi
2026-08-11
Recruiting
AstraZeneca
Phase 3
750
Fukuoka, Kyoto, Nishinomiya-shi, Okayama, Sapporo, Shibuya-ku, Shinjuku-ku, Suita-shi
2026-06-26
Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
NCT07486934Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease
DrugZeleciment basivarsen
Dyne Therapeutics
Phase 3
150
Kashiwazaki, Suita-shi, Toyonaka-Shi, Kodaira, Ube-Shi
2026-05-14
Recruiting
Eli Lilly and Company
Phase 3
1,980
Adachi-ku, Chūōku, Fukuoka, Minato, Mitaka, Suita-shi, Tokyo
2026-02-06
Recruiting
Eli Lilly and Company
Phase 2
60
Chūōku, Kamakura-shi, Suita-shi
2025-12-08
Recruiting
AstraZeneca
Phase 3
1,100
Chiba, Kashiwa, Kawasaki-shi, Kōtoku, Matsuyama, Nagoya, Osaka, Suita-shi
2025-12-04
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
Nagoya-sh, Toyoake Shi, Asahikawa-shi, Suita, Suita-shi, Ōtsu, Chūōku, Fukuoka
2025-09-22
Recruiting
Takeda
Phase 3
150
Chuo-ku, Narashino-shi, Ibaraki, Yokohama, Sendai, Hirakata-shi, Osaka, Suita-shi
2025-08-14
Recruiting
AbbVie
Phase 1/2
325
Nagoya, Kyoto, Suita-shi, Shibuya-ku, Tokyo
2025-07-23
Recruiting
AbbVie
Phase 1/2
602
Nagoya, Kyoto, Suita-shi, Shibuya-ku
2025-06-30
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
450
Kyoto, Suita-shi
2025-05-19
Active, closed
Eli Lilly and Company
Phase 3
600
Chitose, Chūōku, Mihama-ku,Chiba City, Shinjuku-ku, Suita-shi, Takamatsu, Tokyo, Tsuchiura
2025-05-19
Active, closed
Eli Lilly and Company
Phase 3
800
Chitose, Chūōku, Mihama-ku,Chiba City, Shinjuku-ku, Suita-shi, Takamatsu, Tokyo, Tsuchiura
2025-05-15
Active, closed
Eli Lilly and Company
Phase 3
1,400
Chitose, Chūōku, Mihama-ku,Chiba City, Shinjuku-ku, Suita-shi, Takamatsu, Tokyo, Tsuchiura
2025-05-15
Recruiting
Takeda
Phase 3
171
Chuo-ku, Narashino-shi, Ibaraki, Yokohama, Sendai, Hirakata-shi, Osaka, Suita-shi
2025-02-27
Recruiting
Enliven Therapeutics
Phase 1
21
Akita, Sapporo, Suita-shi, Shinjuku-ku
2025-01-23
Active, closed
AbbVie
Phase 2
74
Nagoya, Kashiwa-shi, Suita-shi, Kitaadachi-gun, Chuo-Ku
2024-11-08
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
2,150
Ōgaki, Maebashi, Fukui-shi, Yokohama, Kyoto, Suita-shi, Bunkyō-Ku, Minato-Ku
2024-10-04
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
43
Bunkyō City, Minatoku, Suita-shi, Yonago-shi
2024-04-02
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
Bunkyō City, Kumamoto, Kurume-shi, Kyoto, Matsumoto-shi, Sapporo, Shinjuku-ku, Suita-shi
2024-01-11
Active, closed
AbbVie
Phase 3
614
Nagoya, Sakai-shi, Suita-shi, Bunkyo-ku, Shinjuku-ku, Yamagata, Kofu
2023-12-19
Active, closed
AstraZeneca
Phase 1/2
166
Fukuoka, Shinjuku-ku, Suita-shi
2023-09-29
Active, closed
Eli Lilly and Company
Phase 3
3,127
Wakasugi, Aki-gun, Tsuchiura, Takamatsu, Zentsujichó, Yokohama, Suita-shi, Sōka
2023-06-05
Active, closed
Insmed Incorporated
Phase 2/3
91
Sapporo, Kurume-shi, Tsukuba, Okayama, Suita-Shi
2023-03-07
Active, closed
TRISCEND JAPAN Study
NCT05760989Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases
Edwards Lifesciences
Not applicable
45
Kitakyushu-shi, Isehara-shi, Sendai, Osaka, Suita, Suita-shi, Shinjuku-Ku
2023-02-06
Recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
NCT05652335Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
DrugRamantamig
Janssen Research & Development, LLC
Phase 1
180
Shibuya City, Suita-shi, Tokyo
2022-11-22
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Sapporo, Suita-shi, Aichi, Chiba-shi, Chiba, Gunma, Kanagawa, Osaka, Saitama
2022-11-01
Recruiting
AstraZeneca
Phase 2
454
Chūōku, Kashiwa, Kōtoku, Nagoya, Shinagawa-ku, Suita-shi
2022-09-06
Active, closed
Biogen
Phase 2
416
Toon-shi, Himeji-shi, Kawasaki-shi, Yokohama, Osaka, Suita-shi, Itabashi-ku
2022-08-24
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
372
Kashiwa-shi, Sapporo, Suita-shi, Tokushima, Koto-ku, Osaka
2022-05-03
Active, closed
AbbVie
Phase 1
8
Kashiwa-shi, Sapporo, Kanazawa, Okayama, Suita-shi, Yamagata
2022-03-24
Active, closed
UCB Biopharma SRL
Phase 3
113
Chiba, Isehara, Kitakyushu-shi, Kodaira, Koriyama-shi, Sendai, Shinjuku-ku, Suita-shi
2022-02-02
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 3
626
Kashiwa-shi, Yokohama, Osaki-shi, Suita-shi, Hidaka-shi, Ina-machi, Kitaadati-gun, Nagaizumi-Cho, Sunto-Gun, Bunkyo-ku
2021-11-05
Active, closed
Eli Lilly and Company
Phase 3
2,996
Bunkyō City, Chūōku, Hachiōji, Osaka, Ōbu, Shinjuku, Shinjuku-ku, Suita-shi
2021-08-27
Recruiting
PharmaEssentia Japan K.K.
Phase 3
67
Toon-shi, Tsu, Suita-shi, Bunkyo-ku, Shinjuku-ku, Chuo-shi
2021-01-19
Active, closed
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
NCT04639219Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
102
Chūōku, Kashiwa, Suita-shi
2020-12-30
Active, closed
Eli Lilly and Company
Phase 1
200
Kashiwa, Yokohama, Suita-shi, Nakatogari, Chuo-ku
2020-10-01
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
477
Chūōku, Kashiwa, Suita-shi
2020-08-18
Active, closed
Eisai Inc.
Phase 3
1,400
Obu-shi, Fukuoka, Kobe, Kamakura-shi, Kyoto, Sendai, Osaka, Suita-shi
2020-07-14
Active, closed
AbbVie
Phase 1
85
Kamakura-shi, Osakasayama-shi, Suita-shi, Bunkyo-ku, Chuo-shi
2019-11-08
Active, closed
AstraZeneca
Phase 3
810
Chūōku, Kashiwa, Kitaadachi-gun, Mitaka-shi, Osaka, Suita-shi, Wakayama, Yokohama
2019-04-16
Active, closed
Avelumab Program Rollover Study
NCT03815643Solid Tumors
DrugAvelumab
EMD Serono Research & Development Institute, Inc.
Phase 3
205
Chūōku, Habikino-shi, Kōtoku, Kurume-shi, Osaka, Sendai, Suita-shi
2019-03-22
Rows per page Showing 1–46 of 46
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/suita-shi

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 46 of those studies with a site in Suita-shi.

How many clinical trials are recruiting in Suita-shi?

20 of the 46 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 2 have not yet opened recruitment, 24 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Suita-shi), 46 studies
PhaseStudiesRecruitingShare
Phase 3281260.9%
Phase 27315.2%
Phase 16313%
Phase 1/2326.5%
Not applicable102.2%
Phase 2/3102.2%

Most active sponsors

Lead sponsors with the most studies (Suita-shi)
Lead sponsorStudiesRecruiting
Eli Lilly and Company104
AstraZeneca73
AbbVie62
Alexion Pharmaceuticals, Inc.41
Novo Nordisk A/S31
Takeda22
Akero Therapeutics, Inc11
Biogen10
Bristol-Myers Squibb11
Dyne Therapeutics11
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.